| 1 |
33236485 | Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. | 2021 Mar |
1 |
| 2 |
17500623 | Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. | 2007 May |
1 |
| 3 |
17654295 | Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. | 2007 Aug |
1 |
| 4 |
18058343 | Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. | 2007 Dec |
2 |
| 5 |
15492764 | Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. | 2005 |
2 |
| 6 |
15138759 | Changes in food reward following smoking cessation: a pharmacogenetic investigation. | 2004 Aug |
1 |
| 7 |
14668077 | Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? | 2003 Dec |
3 |
| 8 |
12474115 | Effect of bupropion-SR on REM sleep: relationship to antidepressant response. | 2002 Dec |
1 |